Washington, D.C. — The Consumer Healthcare Products Association (CHPA) issued the following statement today from Scott Melville, president and CEO, regarding the nomination of Robert Califf, M.D. as the next U.S. Food and Drug Administration (FDA) commissioner. Dr. Califf is a prominent cardiologist and researcher who served as the FDA commissioner under President Barack Obama.
“CHPA applauds President Biden’s choice for the next permanent FDA Commissioner. Having previously served at the helm of FDA, Dr. Califf is an excellent choice to lead the Agency at such an important time for public health. In addition, his experience and insights on digital health and technology will be critical for helping to shape the future of FDA and the growth of consumer self-care.
“Once confirmed, we look forward to continuing to work with the new commissioner on shared priorities to strengthen the safety and accessibility of self-care options. Our mutual focus includes important regulatory modernization efforts like OTC Monograph reform implementation, modernization of the regulatory framework for dietary supplements, and expansion of conditions for safe use of nonprescription medicines to enable innovations, including Rx-to-OTC switch, both for drugs and for medical devices.
“OTC medicines, dietary supplements, and consumer medical devices are accessible and affordable healthcare options. Our industry looks forward to working with Dr. Califf and the FDA staff to further promote public health by increasing access to safe, effective, and beneficial consumer healthcare products.”
